- Home
- RNXT vs VIRX Comparison
RNXT vs VIRX Comparison
Compare RNXT & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- VIRX
- Stock Information
- Founded
- RNXT 2012
- VIRX 2007
- Country
- RNXT United States
- VIRX United States
- Employees
- RNXT N/A
- VIRX N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- VIRX Health Care
- Exchange
- RNXT Nasdaq
- VIRX Nasdaq
- Market Cap
- RNXT 24.0M
- VIRX 8.8M
- IPO Year
- RNXT 2021
- VIRX N/A
- Fundamental
- Price
- RNXT $1.00
- VIRX $0.22
- Analyst Decision
- RNXT Strong Buy
- VIRX Buy
- Analyst Count
- RNXT 3
- VIRX 4
- Target Price
- RNXT $6.13
- VIRX $5.50
- AVG Volume (30 Days)
- RNXT 43.8K
- VIRX 146.3K
- Earning Date
- RNXT 11-12-2024
- VIRX 11-07-2024
- Dividend Yield
- RNXT N/A
- VIRX N/A
- EPS Growth
- RNXT N/A
- VIRX N/A
- EPS
- RNXT N/A
- VIRX N/A
- Revenue
- RNXT N/A
- VIRX N/A
- Revenue This Year
- RNXT N/A
- VIRX N/A
- Revenue Next Year
- RNXT N/A
- VIRX N/A
- P/E Ratio
- RNXT N/A
- VIRX N/A
- Revenue Growth
- RNXT N/A
- VIRX N/A
- 52 Week Low
- RNXT $0.53
- VIRX $0.20
- 52 Week High
- RNXT $2.35
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- RNXT 46.64
- VIRX 37.72
- Support Level
- RNXT $0.98
- VIRX $0.20
- Resistance Level
- RNXT $1.02
- VIRX $0.24
- Average True Range (ATR)
- RNXT 0.05
- VIRX 0.01
- MACD
- RNXT -0.00
- VIRX 0.00
- Stochastic Oscillator
- RNXT 31.25
- VIRX 32.00
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.